Article

Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and Safety

2024-08-02

Abstract excerpt

Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up majority of all cases. The standard-of-care (SOC) in HR+/HER2- metastatic BC (MBC) is endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i). ESR1 mutations could impair clinical efficacy of the ETs. Similarly, PIK3CA mutations may serve as a negative prognostic marker. Furthermore...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2f775041-6b8f-5849-8ce2-b78ba3973ba1
DOI: 10.20944/preprints202408.0128.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and SafetyDOI 10.20944/preprints202408.0128.v1Read

Elacestrant in metastatic breast cancer: current advancements and future perspectives.Semantic proximity Read

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?Semantic proximity Read

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.Semantic proximity Read

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.Semantic proximity Read

Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity Read

Targeted therapies for ER+/HER2- metastatic breast cancerSemantic proximity Read

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.Semantic proximity Read

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.Semantic proximity Read

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.Semantic proximity Read

Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Semantic proximity Read

Oral SERDs: Transforming the treatment of advanced breast cancer-Insights from EMBER-3.Semantic proximity Read